Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy Shahd M. HassonaEntsar A. SaadMohamed M. Hassanien PRECLINICAL STUDIES 30 March 2022 Pages: 681 - 689
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA Wenting ChenChenxin QieJun Liu PRECLINICAL STUDIES 11 April 2022 Pages: 690 - 699
The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines Markus HaasTeresa LenzBernhard J Jank PRECLINICAL STUDIES Open access 12 April 2022 Pages: 700 - 708
Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells Wei ChiLianyong ZhangQianyun Zhang PRECLINICAL STUDIES 19 April 2022 Pages: 709 - 717
Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia Chie IshikawaNaoki Mori PRECLINICAL STUDIES 28 April 2022 Pages: 718 - 727
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells Jean Carlos Lipreri da SilvaMaria Fernanda Lopes CarvalhoJoão Agostinho Machado-Neto PRECLINICAL STUDIES 28 April 2022 Pages: 728 - 737
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation Yixuan GuoZhaoyun LiuRong Fu PRECLINICAL STUDIES 16 May 2022 Pages: 738 - 746
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers Hui K. GanSagun ParakhAndrew M. Scott PHASE I STUDIES 11 April 2022 Pages: 747 - 755
Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects Ming-min CaiTing DouWei Qian PHASE I STUDIES 18 April 2022 Pages: 756 - 761
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study Patricia LoRussoMark J. RatainEmiliano Calvo PHASE I STUDIES Open access 25 April 2022 Pages: 762 - 772
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia Margaret T. KasnerMolly B. HalloranJames E. Thompson PHASE I STUDIES 17 May 2022 Pages: 773 - 781
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin Luke S McLeanTessa A MorrisDanny Rischin PHASE II STUDIES 18 April 2022 Pages: 782 - 788
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience Wen-Chi WuTzu-Yuan LinSan-Chi Chen PHASE II STUDIES Open access 28 April 2022 Pages: 789 - 797
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA Daniel Tobias MichaeliMackenzie MillsPanos Kanavos PHASE III STUDIES Open access 07 April 2022 Pages: 798 - 809
The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis Li-Fang MengJian-Feng HuangHan-Lei Wang Review 12 April 2022 Pages: 810 - 817
Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients Kangsong TianWei QiDelei Song Review 18 April 2022 Pages: 818 - 830
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis Yunxia TaoYu ZhouYuankai Shi Review 18 April 2022 Pages: 831 - 840
Practical consideration for successful sequential tumor biopsies in first-in-human trials Takafumi KoyamaToshio ShimizuNoboru Yamamoto Short Report Open access 11 April 2022 Pages: 841 - 849
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report Xiang TianQiong LiaoYuanjian Cheng SHORT REPORT 20 April 2022 Pages: 850 - 853
Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1 Yiming TaoJie HanYongsheng Li Short Report 03 May 2022 Pages: 854 - 857
Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma Guanglin ShiYuyan LuoBojin Zhu SHORT REPORT 07 May 2022 Pages: 858 - 860
Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis Junlong MaWenjing ChenGuoping Yang Case Report 21 May 2022 Pages: 861 - 867
Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas Yingjun ZhangC. H. WongHerbert H. F. Loong Letters to the Editor 11 April 2022 Pages: 868 - 869
A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment Rui JiangDongguang WeiQianqian Duan Letters to the Editor 12 May 2022 Pages: 870 - 873